EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Translational Advances in Oncogene and Tumor-Suppressor Gene Research

Radoslav Stojchevski iD, Edward Agus Sutanto iD, Rinni Sutanto, Nikola Hadzi-Petrushev iD, Mitko Mladenov iD, Sajal Raj Singh, Jitendra Kumar Sinha iD, Shampa Ghosh iD, Bhuvaneshwar Yarlagadda, Krishna Kumar Singh iD, Prashant Verma, Sonali Sengupta iD und 2 weitere

Cancers · 17.03.2025 · 17 (6) · 1008

DOI: 10.3390/cancers17061008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.03.2025. Verfasst von Radoslav Stojchevski und 13 weiteren Autor:innen. Beteiligte Einrichtung: Friedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, New York, NY 10022, USA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 372 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gerald J. and Dorothy R. Friedman New York Foundation for Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer, characterized by the uncontrolled proliferation of cells, is one of the leading causes of death globally, with approximately one in five people developing the disease in their lifetime. While many driver genes were identified decades ago, and most cancers can be classified based on morphology and progression, there is still a significant gap in knowledge about genetic aberrations and nuclear DNA damage. The study of two critical groups of genes—tumor suppressors, which inhibit proliferation and promote apoptosis, and oncogenes, which regulate proliferation and survival—can help to understand the genomic causes behind tumorigenesis, leading to more personalized approaches to diagnosis and treatment. Aberration of tumor suppressors, which undergo two-hit and loss-of-function mutations, and oncogenes, activated forms of proto-oncogenes that experience one-hit and gain-of-function mutations, are responsible for the dysregulation of key signaling pathways that regulate cell division, such as p53, Rb, Ras/Raf/ERK/MAPK, PI3K/AKT, and Wnt/β-catenin. Modern breakthroughs in genomics research, like next-generation sequencing, have provided efficient strategies for mapping unique genomic changes that contribute to tumor heterogeneity. Novel therapeutic approaches have enabled personalized medicine, helping address genetic variability in tumor suppressors and oncogenes. This comprehensive review examines the molecular mechanisms behind tumor-suppressor genes and oncogenes, the key signaling pathways they regulate, epigenetic modifications, tumor heterogeneity, and the drug resistance mechanisms that drive carcinogenesis. Moreover, the review explores the clinical application of sequencing techniques, multiomics, diagnostic procedures, pharmacogenomics, and personalized treatment and prevention options, discussing future directions for emerging technologies.

Schlagwörter

Stichwörter der Autor:innen

cancer researchemerging technologymolecular pathwaysoncogenestargeted cancer therapytumor heterogeneitytumor microenvironmenttumor-suppressor genes

Autor:innen und Institutionen

  • Friedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, New York, NY 10022, USA.
  • Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA.
  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA.
  • CUNY School of Medicine, The City College of New York, 160 Convent Avenue, New York, NY 10031, USA.
  • New York Institute of Technology College of Osteopathic Medicine, Glen Head, NY 11545, USA.
  • Faculty of Natural Sciences and Mathematics, Institute of Biology, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia.

ORCID-Profile: Radoslav Stojchevski, Edward Agus Sutanto, Nikola Hadzi-Petrushev, Mitko Mladenov, Jitendra Kumar Sinha, Shampa Ghosh, Krishna Kumar Singh, Sonali Sengupta, Rakesh Bhaskar, Dimiter Avtanski

Förderung

  • Gerald J. and Dorothy R. Friedman New York Foundation for Medical Research

Zitieren

APA

Stojchevski, R., Sutanto, E. A., Sutanto, R., Hadzi-Petrushev, N., Mladenov, M., Singh, S. R., Sinha, J. K., Ghosh, S., Yarlagadda, B., Singh, K. K., Verma, P., Sengupta, S., Bhaskar, R., & Avtanski, D. (2025). Translational Advances in Oncogene and Tumor-Suppressor Gene Research. Cancers, 17(6), 1008. https://doi.org/10.3390/cancers17061008

Vancouver

Stojchevski R, Sutanto EA, Sutanto R, Hadzi-Petrushev N, Mladenov M, Singh SR, et al. Translational Advances in Oncogene and Tumor-Suppressor Gene Research. Cancers. 2025;17(6):1008. doi:10.3390/cancers17061008

BibTeX
@article{Stojchevski2025,
  author = {Stojchevski, Radoslav and Sutanto, Edward Agus and Sutanto, Rinni and Hadzi-Petrushev, Nikola and Mladenov, Mitko and Singh, Sajal Raj and Sinha, Jitendra Kumar and Ghosh, Shampa and Yarlagadda, Bhuvaneshwar and Singh, Krishna Kumar and Verma, Prashant and Sengupta, Sonali and Bhaskar, Rakesh and Avtanski, Dimiter},
  title = {Translational Advances in Oncogene and Tumor-Suppressor Gene Research},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {6},
  pages = {1008},
  doi = {10.3390/cancers17061008}
}
Kostenlos starten →